The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy
Abstract
Pegylated liposomal doxorubicin (Doxil, Caelyx) is a formulation of doxorubicin in poly(ethylene glycol)-coated (stealth) liposomes with a prolonged circulation time and unique toxicity profile. We review the preclinical and clinical pharmacology as well as recent clinical data obtained in specific cancer types. Doxil liposomes retain the drug payload during circulation and accumulate preferentially in tissues with increased microvascular permeability, as often is the case of tumors. Doxil toxicity profile is drastically different from that of doxorubicin, and is characterized by dominant and dose-limiting mucocutaneous toxicities, mild myelosuppression, minimal alopecia, and no apparent cardiac toxicity. Although the single maximum tolerated dose (MTD) of Doxil is actually lower than that of conventionally administered doxorubicin, the cumulative MTD dose of Doxil may be substantially greater than that of free doxorubicin. Doxil is probably one of the most active agents in AIDS-related Kaposi's sarcoma and has a definite role in management of recurrent ovarian cancer. The potential of Doxil in the treatment of other cancer types and the opportunities it offers in combination with other drugs and therapeutic modalities are under active investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Doxorubicin encapsulated in a liposome (Doxil), administrated intravenously, has been used to treat breast cancer, ovarian cancer, Kaposi's sarcoma, and other solid tumors.”
From Hyaluronic a cid–doxorubicin nanoparticles for targeted treatment of colorectal cancer (2021) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Haran, G., Cohen, R., Bar, L. K., & Barenholz, Y. (1993) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(93)90105-9 · Cited by 934
Research works printed but not linked: 76
- Lasic D. D., 1998, Medical Applications of Liposomes
- Janoff A. S., 1999, Liposomes: Rational Design
- Markman M, 1997, Drugs, 54, 1
- Alberts D. S, 1997, Oncology, 11, 1
- Lasic D., 1995, Stealth Liposomes
- 10.1007/978-3-662-22115-0 · DOI
- 10.1073/pnas.88.24.11460 · DOI · Paper page
- 10.1016/0005-2736(90)90091-2 · DOI · Paper page
- 10.1016/0014-5793(92)80947-F · DOI · Paper page
- Gabizon A., 1990, Cancer Res., 50, 6371
- Yuan F., 1995, Cancer Res., 55, 3752
- 10.1023/A:1018907715905 · DOI · Paper page
- 10.1177/096032719601500906 · doi:10.1177/096032719601500906
- 10.1016/S0169-409X(96)00476-0 · DOI · Paper page
- 10.1038/bjc.1997.84 · DOI
- 10.2165/00003495-199700544-00005 · DOI · Paper page
- 10.3109/10611869608996830 · DOI
- Hong R-L., 1999, Clin. Cancer Res., 5, 3645
- 10.3109/08982109909035551 · DOI
- 10.3109/08982109309150734 · DOI
- Working P. K., 1999, J. Pharmacol Exp. Ther., 289, 1128
- Gabizon A., 1994, Cancer Res., 54, 987
- Martin F. J, 1997, Oncology, 11, 11
- 10.1016/S0009-9236(97)90162-4 · doi:10.1016/s0009-9236(97)90162-4
- 10.1002/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z · DOI · Paper page
- 10.1002/j.1552-4604.1996.tb04152.x · DOI · Paper page
- Stewart S., 1997, Oncology, 11, 33
- 10.1002/(SICI)1097-0142(19990701)86:1<72::AID-CNCR12>3.0.CO;2-1 · DOI · Paper page
- Uziely B., 1995, J. Clin. Oncol., 13, 1777, 10.1200/JCO.1995.13.7.1777 · DOI · Paper page
- Ranson M. R., 1997, J. Clin. Oncol., 15, 3185, 10.1200/JCO.1997.15.10.3185 · DOI · Paper page
- Muggia F. M., 1997, J. Clin. Oncol., 15, 987, 10.1200/JCO.1997.15.3.987 · DOI · Paper page
- Hamilton A., 1998, Breast Cancer Res. Treat., 50, 324
- 10.1007/978-3-662-22115-0_11 · DOI
- 10.1097/00001813-199801000-00005 · DOI
- 10.1006/bbrc.1994.2658 · DOI
- 10.1097/00001813-200002000-00009 · DOI
- Huang S. K., 1994, Cancer Res., 54, 2186
- 10.1007/BF00685327 · DOI
- Gill P. S., 1995, J. Clin. Oncol., 13, 996, 10.1200/JCO.1995.13.4.996 · DOI · Paper page
- Vail D. M., 1998, Clin. Cancer Res., 4, 1567
- 10.1023/A:1008216430806 · DOI · Paper page
- 10.1023/A:1008365716693 · DOI · Paper page
- 10.1093/jnci/87.20.1556 · doi:10.1093/jnci/87.20.1556
- 10.1023/A:1008364529537 · doi:10.1023/a:1008364529537
- 10.1016/S0936-6555(05)80089-5 · doi:10.1016/s0936-6555(05)80089-5
- Harrison M., 1995, J. Clin. Oncol., 13, 914, 10.1200/JCO.1995.13.4.914 · doi:10.1200/jco.1995.13.4.914
- Northfelt D. W., 1998, J. Clin. Oncol., 16, 2445, 10.1200/JCO.1998.16.7.2445 · DOI · Paper page
- Stewart S., 1998, J. Clin. Oncol., 16, 683, 10.1200/JCO.1998.16.2.683 · DOI · Paper page
- Gill P. S., 1996, J. Clin. Oncol., 14, 2353, 10.1200/JCO.1996.14.8.2353 · DOI · Paper page
- Northfelt D. W., 1997, J. Clin. Oncol., 15, 653, 10.1200/JCO.1997.15.2.653 · DOI · Paper page
- Gordon A. N., 2000, Proc. Am. Soc. Clin. Oncol., 19, 1504
- Klein P., 2000, Proc. Am. Soc. Oncol., 19, 410a
- 10.1016/S0190-9622(00)90007-0 · doi:10.1016/s0190-9622(00)90007-0
- 10.1023/A:1008386822906 · doi:10.1023/a:1008386822906
- Ellerhorst J. A., 1999, Oncol. Rep., 6, 1097
- 10.1023/A:1008439013169 · DOI
- Judson I., 1999, Proc. Am. Soc. Clin. Oncol., 18, 541a
- 10.1023/A:1008319618638 · doi:10.1023/a:1008319618638
- 10.1002/(SICI)1096-8652(199801)57:1<85::AID-AJH16>3.0.CO;2-8 · doi:10.1002/(sici)1096-8652(199801)57:1<85::aid-ajh16>3.0.co;2-8
- 10.1016/S0959-8049(99)81571-8 · doi:10.1016/s0959-8049(99)81571-8
- Langley R. E., 1998, Proc. Am. Soc. Clin. Oncol., 17, 246a
- Wasserheit C., 1999, Proc. Am. Soc. Clin. Oncol., 18, 167a
- 10.1023/A:1008323200102 · DOI
- Lokich J., 1983, J. Clin. Oncol., 1, 24, 10.1200/JCO.1983.1.1.24 · DOI
- Samuels B. L., 1987, Cancer Treat. Rep., 71, 971
- Krishna R., 1999, Anticancer Res., 19, 2885
- Cabanes A., 1999, Clin. Cancer Res., 5, 687
- Colbern G. T., 1998, Breast Cancer Res. Treat., 50, 320
- Koukourakis M. I., 1999, J. Clin. Oncol., 17, 3512, 10.1200/JCO.1999.17.11.3512 · DOI · Paper page
- Lopez de Menezes D. E., 1998, Cancer Res., 58, 3320
- 10.1016/S0168-3659(97)00236-8 · DOI · Paper page
- 10.1073/pnas.92.5.1327 · DOI · Paper page
- 10.1038/bjc.1996.625 · DOI · Paper page
- 10.3109/08982109009036010 · DOI
- 10.1016/B978-044482917-7/50035-1 · doi:10.1016/b978-044482917-7/50035-1
- Martin F. J. Medical Applications of Liposomes, D. D. Lasic, D. Papahadjopoulos. Elsevier, New York 1998; 654
Cited by
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Liposomes as nanomedical devices
Bozzuto, G., & Molinari, A. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s68861 · Cited by 2,261
Tumor delivery of macromolecular drugs based on the EPR effect
Torchilin, V. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.03.011 · Cited by 2,032
Exploiting the enhanced permeability and retention effect for tumor targeting
Iyer, A. K., Khaled, G., Fang, J., & Maeda, H. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.07.005 · Cited by 1,846
Pharmacokinetics of Pegylated Liposomal Doxorubicin: Review of Animal and Human Studies
Gabizon, A., Shmeeda, H., & Barenholz, Y. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342050-00002 · Cited by 1,634
Self-citationPolymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect
Maeda, H., Bharate, G. Y., & Daruwalla, J. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.11.010 · Cited by 1,168
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016
Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., D'Amico, T. A., Dilling, T. J., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0031 · Cited by 736
Therapeutic EphA2 Gene Targeting In vivo Using Neutral Liposomal Small Interfering RNA Delivery
Landen, C. N., Chavez-Reyes, A., Bucana, C., Schmandt, R., Deavers, M. T., Lopez-Berestein, G., & Sood, A. K. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0530 · Cited by 675
Lukyanov, A. N., & Torchilin, V. P. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.12.004 · Cited by 655
Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects
Maruyama, K. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.09.003 · Cited by 601
Greish, K. (2007) · Journal of Drug Targeting · doi:10.1080/10611860701539584 · Cited by 600
Andresen, T. L., Jensen, S. S., & Jørgensen, K. (2005) · Progress in Lipid Research · doi:10.1016/j.plipres.2004.12.001 · Cited by 580
Passive and Active Drug Targeting: Drug Delivery to Tumors as an Example
Torchilin, V. P. (2010) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-00477-3_1 · Cited by 573
Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention
Henriksen, P. A. (2018) · Heart · doi:10.1136/heartjnl-2017-312103 · Cited by 536
Dromi, S., Frenkel, V., Luk, A., Traughber, B., Angstadt, M., Bur, M., Poff, J., Xie, J., Libutti, S. K., Li, K. C. P., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2443 · Cited by 492
State-of-the-art materials for ultrasound-triggered drug delivery
Sirsi, S. R., & Borden, M. A. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.12.010 · Cited by 488
Chanan-Khan, A., Szebeni, J., Savay, S., Liebes, L., Rafique, N. M., Alving, C. R., & Muggia, F. M. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg374 · Cited by 479
Extracellularly Activated Nanocarriers: A New Paradigm of Tumor Targeted Drug Delivery
Gullotti, E., & Yeo, Y. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900090z · Cited by 473
Determination of Doxorubicin Levels in Whole Tumor and Tumor Nuclei in Murine Breast Cancer Tumors
Laginha, K. M., Verwoert, S., Charrois, G. J. R., & Allen, T. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0343 · Cited by 441
Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles
Alavi, M., & Hamidi, M. (2019) · Drug Metabolism and Personalized Therapy · doi:10.1515/dmpt-2018-0032 · Cited by 405
Bioavailability of phytochemicals and its enhancement by drug delivery systems
Aqil, F., Munagala, R., Jeyabalan, J., & Vadhanam, M. V. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.02.032 · Cited by 398
Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status
van der Meel, R., Vehmeijer, L. J. C., Kok, R. J., Storm, G., & van Gaal, E. V. B. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.012 · Cited by 398
Liposomal Delivery Systems: Design Optimization and Current Applications
Abu Lila, A. S., & Ishida, T. (2017) · Biological & Pharmaceutical Bulletin · doi:10.1248/bpb.b16-00624 · Cited by 382
Challenges in Development of Targeted Liposomal Therapeutics
Sawant, R. R., & Torchilin, V. P. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9330-0 · Cited by 379
Design of virus-based nanomaterials for medicine, biotechnology, and energy
Wen, A. M., & Steinmetz, N. F. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00287g · Cited by 379
Feng, S.-S., & Chien, S. (2003) · Chemical Engineering Science · doi:10.1016/s0009-2509(03)00234-3 · Cited by 364
Peptide and protein drug delivery to and into tumors: challenges and solutions
Torchilin, V. P., & Lukyanov, A. N. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02623-0 · Cited by 363
Multifunctional Micellar Nanomedicine for Cancer Therapy
Blanco, E., Kessinger, C. W., Sumer, B. D., & Gao, J. (2009) · Experimental Biology and Medicine · doi:10.3181/0808-mr-250 · Cited by 332
Nanotechnological carriers for cancer chemotherapy: The state of the art
Estanqueiro, M., Amaral, M. H., Conceição, J., & Sousa Lobo, J. M. (2015) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2014.12.041 · Cited by 298
pH-Sensitive liposomes-principle and application in cancer therapy
Karanth, H., & Murthy, R. S. R. (2007) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.59.4.0001 · Cited by 294
Lukyanov, A. N., Elbayoumi, T. A., Chakilam, A. R., & Torchilin, V. P. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.08.007 · Cited by 294
Agger, E. M., Rosenkrands, I., Hansen, J., Brahimi, K., Vandahl, B. S., Aagaard, C., Werninghaus, K., Kirschning, C., Lang, R., Christensen, D., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003116 · Cited by 287
Drug resistance in multiple myeloma
Robak, P., Drozdz, I., Szemraj, J., & Robak, T. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.09.001 · Cited by 283
Greish, K., Fang, J., Inutsuka, T., Nagamitsu, A., & Maeda, H. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342130-00002 · Cited by 278
Pros and Cons of the Liposome Platform in Cancer Drug Targeting
Gabizon, A. A., Shmeeda, H., & Zalipsky, S. (2006) · Journal of Liposome Research · doi:10.1080/08982100600848769 · Cited by 272
Self-citationDesign of Nanoparticle-Based Carriers for Targeted Drug Delivery
Yu, X., Trase, I., Ren, M., Duval, K., Guo, X., & Chen, Z. (2016) · Journal of Nanomaterials · doi:10.1155/2016/1087250 · Cited by 265
Nanomedicine in cancer therapy: Innovative trends and prospects
Blanco, E., Hsiao, A., Mann, A. P., Landry, M. G., Meric‐Bernstam, F., & Ferrari, M. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01941.x · Cited by 265
Leonard, R. C. F., Williams, S., Tulpule, A., Levine, A. M., & Oliveros, S. (2009) · The Breast · doi:10.1016/j.breast.2009.05.004 · Cited by 257
The Rise and Rise of Stealth Nanocarriers for Cancer Therapy: Passive Versus Active Targeting
Huynh, N. T., Roger, E., Lautram, N., Benoît, J.-P., & Passirani, C. (2010) · Nanomedicine · doi:10.2217/nnm.10.113 · Cited by 164
The in vivo fate of polymeric micelles
Cai, Y., Qi, J., Lu, Y., He, H., & Wu, W. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114463 · Cited by 154
Cai, L., Xu, G., Shi, C., Guo, D., Wang, X., & Luo, J. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.10.044 · Cited by 151
Engineered nanoparticles, How brain friendly is this new guest?
Cupaioli, F. A., Zucca, F. A., Boraschi, D., & Zecca, L. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.05.002 · Cited by 139
Doxorubicin-induced cardiotoxicity: causative factors and possible interventions
Jones, I. C., & Dass, C. R. (2022) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgac063 · Cited by 91
Hyaluronic a cid–doxorubicin nanoparticles for targeted treatment of colorectal cancer
Pan, D. C., Krishnan, V., Salinas, A. K., Kim, J., Sun, T., Ravid, S., Peng, K., Wu, D., Nurunnabi, M., Nelson, J. A., et al. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10166 · Cited by 42
Gupta, A., Kaur, C. D., Saraf, S., & Saraf, S. (2017) · Journal of Receptors and Signal Transduction · doi:10.3109/10799893.2016.1147581 · Cited by 27
Metadata
- Authors
- Gabizon, A. A.
- Venue
- Cancer Investigation
- Publisher
- Informa UK Limited
- Published
- 2001-01
- Volume
- 19
- Issue
- 4
- Pages
- 424-436
- ISSN
- 0735-7907
- 1532-4192
- Cited by
- 458
- References
- 1
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.